drugset / Trial / NCT00106613

A Research Study for Patients With Metastatic Renal Cell Carcinoma

NCT00106613

Phase 2 Completed 30 enrolled Celgene Corporation
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the activity of FK228 in metastatic renal cell carcinoma (RCC) patients who have developed progressive disease (PD) following or during treatment with immunotherapy.

Timeline

Start
2003-05-01
Primary completion
2004-08-01
Completion
2004-08-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Romidepsin Peptide 13 mg/m2 Intravenous